J&J fi­nal­izes $25M set­tle­ment, lay­ing Rem­i­cade an­titrust al­le­ga­tions to rest

A Penn­syl­va­nia fed­er­al judge on Wednes­day ce­ment­ed a $25 mil­lion set­tle­ment in a class ac­tion suit al­leg­ing John­son & John­son blocked biosim­i­lar com­pe­ti­tion to its im­muno­sup­pres­sive drug Rem­i­cade.

First ap­proved in 1998 for Crohn’s dis­ease, Rem­i­cade (a TNF in­hibitor bi­o­log­ic al­so known as in­flix­imab) has since been cleared in a slate of oth­er im­mune-me­di­at­ed con­di­tions, in­clud­ing ul­cer­a­tive col­i­tis, pso­ri­at­ic arthri­tis and rheuma­toid arthri­tis. How­ev­er, the year­ly cost for some pa­tients reach­es $26,000, ac­cord­ing to a com­plaint up­dat­ed in 2018.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.